253 results on '"Mariani, Luciano"'
Search Results
2. Public health value of universal HPV vaccination
- Author
-
Audisio, Riccardo A., Icardi, Giancarlo, Isidori, Andrea M., Liverani, Carlo A., Lombardi, Alberto, Mariani, Luciano, Mennini, Francesco Saverio, Mitchell, David A., Peracino, Andrea, Pecorelli, Sergio, Rezza, Giovanni, Signorelli, Carlo, Rosati, Giovanni Vitali, and Zuccotti, Gian Vincenzo
- Published
- 2016
- Full Text
- View/download PDF
3. Onclarity Human Papillomavirus Extended Genotyping in the Management of Cervical Intraepithelial Neoplasia 2+ Lesions
- Author
-
Bottari, Fabio, Iacobone, Anna Daniela, Boveri, Sara, Preti, Eleonora Petra, Franchi, Dorella, Mariani, Luciano, Preti, Mario, Landoni, Fabio, Passerini, Rita, and Sandri, Maria Teresa
- Published
- 2019
- Full Text
- View/download PDF
4. SIIV position paper: clinical approach to vulval diseases. Need for quality standards
- Author
-
CARRIERO, Carmine, primary, BELFIORE, Pina, additional, CORAZZA, Monica, additional, CRIPPA, Stefano, additional, DE MAGNIS, Angelina, additional, MARIANI, Luciano, additional, MICHELETTI, Leonardo, additional, PRETI, Eleonora P., additional, PRETI, Mario, additional, RADICI, Gianluigi, additional, SALVINI, Camilla, additional, TADDEI, Gianluigi, additional, TOSTI, Giulio, additional, and VIRGILI, Annarosa, additional
- Published
- 2022
- Full Text
- View/download PDF
5. Merkel cell carcinoma: new insights into pathogenesis
- Author
-
Curzio, Gianfranca, Paolini, Francesca, Cota, Carlo, Donati, Pietro, Di Mattia, Cinzia, Mariani, Luciano, Migliano, Emilia, and Venuti, Aldo
- Published
- 2017
- Full Text
- View/download PDF
6. The clinical implementation of primary HPV screening
- Author
-
Mariani, Luciano, Igidbashian, Sarah, Sandri, Maria Teresa, Vici, Patrizia, and Landoni, Fabio
- Published
- 2017
- Full Text
- View/download PDF
7. Overview of the benefits and potential issues of the nonavalent HPV vaccine
- Author
-
Mariani, Luciano, Preti, Mario, Cristoforoni, Paolo, Stigliano, Carlo M., and Perino, Antonio
- Published
- 2017
- Full Text
- View/download PDF
8. Immunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse models
- Author
-
Venuti, Aldo, Curzio, Gianfranca, Mariani, Luciano, and Paolini, Francesca
- Published
- 2015
- Full Text
- View/download PDF
9. Early Direct and Indirect Impact of Quadrivalent HPV (4HPV) Vaccine on Genital Warts: a Systematic Review
- Author
-
Mariani, Luciano, Vici, Patrizia, Suligoi, Barbara, Checcucci-Lisi, Giovanni, and Drury, Rosybel
- Published
- 2015
- Full Text
- View/download PDF
10. Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological samples of HC2-positive patients
- Author
-
Benevolo, Maria, Terrenato, Irene, Mottolese, Marcella, Marandino, Ferdinando, Carosi, Mariantonia, Rollo, Francesca, Ronchetti, Livia, Muti, Paola, Mariani, Luciano, Sindico, Stefano, Vocaturo, Giuseppe, and Vocaturo, Amina
- Published
- 2011
11. Registi dentro e fuori dal set
- Author
-
Mariani, Luciano
- Published
- 2022
- Full Text
- View/download PDF
12. Lack of association between genetic variants in the mannose-binding lectin 2 (MBL2) gene and HPV infection
- Author
-
Parrella, Paola, Seripa, Davide, Matera, Maria G., Rinaldi, Monica, Signori, Emanuela, Gravina, Carolina, Gallo, Antonietta P., Prencipe, Maria, Grandone, Elvira, Mariani, Luciano, Cordiali, Paola, Di Carlo, Aldo, Stentella, Patrizia, Pachì, Antonio, and Fazio, Vito M.
- Published
- 2007
13. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
- Author
-
de Sanjose, Silvia, Quint, Wim GV, Alemany, Laia, Geraets, Daan T, Klaustermeier, Jo Ellen, Lloveras, Belen, Tous, Sara, Felix, Ana, Bravo, Luis Eduardo, Shin, Hai-Rim, Vallejos, Carlos S, de Ruiz, Patricia Alonso, Lima, Marcus Aurelho, Guimera, Nuria, Clavero, Omar, Alejo, Maria, Llombart-Bosch, Antonio, Cheng-Yang, Chou, Tatti, Silvio Alejandro, Kasamatsu, Elena, Iljazovic, Ermina, Odida, Michael, Prado, Rodrigo, Seoud, Muhieddine, Grce, Magdalena, Usubutun, Alp, Jain, Asha, Suarez, Gustavo Adolfo Hernandez, Lombardi, Luis Estuardo, Banjo, Aekunbiola, Menéndez, Clara, Domingo, Efrén Javier, Velasco, Julio, Nessa, Ashrafun, Chichareon, Saibua C Bunnag, Qiao, You Lin, Lerma, Enrique, Garland, Suzanne M, Sasagawa, Toshiyuki, Ferrera, Annabelle, Hammouda, Doudja, Mariani, Luciano, Pelayo, Adela, Steiner, Ivo, Oliva, Esther, Meijer, Chris JLM, Al-Jassar, Waleed Fahad, Cruz, Eugenia, Wright, Thomas C, Puras, Ana, Llave, Cecilia Ladines, Tzardi, Maria, Agorastos, Theodoros, Garcia-Barriola, Victoria, Clavel, Christine, Ordi, Jaume, Andújar, Miguel, Castellsagué, Xavier, Sánchez, Gloria I, Nowakowski, Andrzej Marcin, Bornstein, Jacob, Muñoz, Nubia, and Bosch, F Xavier
- Published
- 2010
- Full Text
- View/download PDF
14. Interaction between glutathione-S-transferase polymorphisms, smoking habit, and HPV infection in cervical cancer risk
- Author
-
Palma, Selena, Novelli, Flavia, Padua, Luca, Venuti, Aldo, Prignano, Grazia, Mariani, Luciano, Cozzi, Renata, Tirindelli, Donatella, and Testa, Antonella
- Published
- 2010
- Full Text
- View/download PDF
15. Hot flushes in women with breast cancer: state of the art and future perspectives
- Author
-
Barba, Maddalena, Pizzuti, Laura, Sergi, Domenico, Maugeri-Saccà, Marcello, Vincenzoni, Cristina, Conti, Francesca, Tomao, Federica, Vizza, Enrico, Di Lauro, Luigi, Di Filippo, Franco, Carpano, Silvia, Mariani, Luciano, and Vici, Patrizia
- Published
- 2014
- Full Text
- View/download PDF
16. [HPV vaccination: not only female adolescents and not only prophylactic. Review and position paper of the Italian HPV Study Group (IHSG)]
- Author
-
Origoni, Massimo, Cristoforoni, Paolo, Mariani, Luciano, Costa, Silvano, Preti, Mario, Sandri, Maria T, Preti, Eleonora P, Ghelardi, Alessandro, Perino, Antonio, Origoni, Massimo, Cristoforoni, Paolo, Mariani, Luciano, Costa, Silvano, Preti, Mario, Sandri, Maria T, Preti, Eleonora P, Ghelardi, Alessandro, and Perino, Antonio
- Subjects
Adult ,Male ,HPV ,Adolescent ,Italy ,Papillomavirus Infections ,Vaccination ,Age Factors ,Humans ,Uterine Cervical Neoplasms ,Female ,Papillomavirus Vaccines - Abstract
HPV vaccination has been introduced in clinical practice in recent years and represents the most effective strategy of primary prevention of cervical carcinoma and of female genital preneoplastic conditions. One of the major issues of the subject is represented by vaccination coverage of the target population. Since its introduction, HPV vaccine efficacy has been progressively demonstrated also towards extragenital HPV-correlated conditions and in males too. Moreover, even subjects of older age groups or subjects who already had HPV infections have been demonstrated to received benefits from vaccination, due to improvements of their immunological response. Recently, vaccine efficacy has also been investigated in terms of adjuvant administration after treatments of preneoplastic or benign conditions of the female lower genital tract caused by HPVs; preliminary results indicate an interesting and promising field of application. On this basis, in this article an analysis of the state of the art has been performed, with specific regard to the Italian scenario and with the focus of future perspectives of implementation of the HPV vaccination policy. From the available evidences, the Italian HPV Study Group recommends the extension of systematic HPV vaccination to males too, to adult subjects and also after conservative treatment of genital HPV correlated conditions.
- Published
- 2019
17. Immunohistochemical expression of p16INK4a is predictive of HR-HPV infection in cervical low-grade lesions
- Author
-
Benevolo, Maria, Mottolese, Marcella, Marandino, Ferdinando, Vocaturo, Giuseppe, Sindico, Roberto, Piperno, Giulia, Mariani, Luciano, Sperduti, Isabella, Canalini, Paola, Donnorso, Raffaele P, and Vocaturo, Amina
- Published
- 2006
- Full Text
- View/download PDF
18. Beta HPV Type 15 Can Interfere With NF-κB Activity and Apoptosis in Human Keratinocytes
- Author
-
Paolini, Francesca, primary, Zaccarini, Marco, additional, Francesconi, Arianna, additional, Mariani, Luciano, additional, Muscardin, Luca, additional, Donati, Pietro, additional, and Venuti, Aldo, additional
- Published
- 2020
- Full Text
- View/download PDF
19. Comparative evaluation of nm23 and p16 expression as biomarkers of high-risk human papillomavirus infection and cervical intraepithelial neoplasia 2+ lesions of the uterine cervix
- Author
-
Benevolo, Maria, Terrenato, Irene, Mottolese, Marcella, Marandino, Ferdinando, Muti, Paola, Carosi, Mariantonia, Rollo, Francesca, Ronchetti, Livia, Mariani, Luciano, Vocaturo, Giuseppe, and Vocaturo, Amina
- Published
- 2010
- Full Text
- View/download PDF
20. The Ringlike Pattern in Vulvar Melanosis: A New Dermoscopic Clue for Diagnosis
- Author
-
Ferrari, Angela, Buccini, Pierluigi, Covello, Renato, De Simone, Paola, Silipo, Vitaliano, Mariani, Giustino, Eibenschutz, Laura, Mariani, Luciano, and Catricalà, Caterina
- Published
- 2008
21. HPV Prevalence Among Healthy Italian Male Sexual Partners of Women With Cervical HPV Infection
- Author
-
Benevolo, Maria, Mottolese, Marcella, Marandino, Ferdinando, Carosi, Mariantonia, Diodoro, Maria Grazia, Sentinelli, Steno, Visca, Paolo, Rollo, Francesca, Mariani, Luciano, Vocaturo, Giuseppe, Sindico, Roberto, Terrenato, Irene, Donnorso, Raffaele Perrone, and Vocaturo, Amina
- Published
- 2008
- Full Text
- View/download PDF
22. Supp_Table_1 – Supplemental material for Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting
- Author
-
Benedetto, Anna Di, Ercolani, Cristiana, Pizzuti, Laura, Angelucci, Domenico, Sergi, Domenico, Marinelli, Camilla, Iezzi, Laura, Sperati, Francesca, Terrenato, Irene, Mazzotta, Marco, Mariani, Luciano, Vizza, Enrico, Paoletti, Giancarlo, Tomao, Silverio, Maugeri-Saccà, Marcello, Barba, Maddalena, Tinari, Nicola, Natoli, Clara, Ciliberto, Gennaro, Grassadonia, Antonino, and Vici, Patrizia
- Subjects
110203 Respiratory Diseases ,FOS: Clinical medicine ,111702 Aged Health Care ,FOS: Health sciences ,111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified ,111299 Oncology and Carcinogenesis not elsewhere classified - Abstract
Supplemental material, Supp_Table_1 for Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting by Anna Di Benedetto, Cristiana Ercolani, Laura Pizzuti, Domenico Angelucci, Domenico Sergi, Camilla Marinelli, Laura Iezzi, Francesca Sperati, Irene Terrenato, Marco Mazzotta, Luciano Mariani, Enrico Vizza, Giancarlo Paoletti, Silverio Tomao, Marcello Maugeri-Saccà, Maddalena Barba, Nicola Tinari, Clara Natoli, Gennaro Ciliberto, Antonino Grassadonia and Patrizia Vici in Therapeutic Advances in Medical Oncology
- Published
- 2019
- Full Text
- View/download PDF
23. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience
- Author
-
Pizzuti, Laura, Giordano, Antonio, Michelotti, Andrea, Mazzotta, Marco, Natoli, Clara, Gamucci, Teresa, De Angelis, Claudia, Landucci, Elisabetta, Diodati, Lucrezia, Iezzi, Laura, Mentuccia, Lucia, Fabbri, Agnese, Barba, Maddalena, Sanguineti, Giuseppe, Marchetti, Paolo, Tomao, Silverio, Mariani, Luciano, Paris, Ida, Lorusso, Vito, Vallarelli, Simona, Cassano, Alessandra, Airoldi, Francesca, Orlandi, Armando, Moscetti, Luca, Sergi, Domenico, Sarobba, Maria Giuseppina, Tonini, Giuseppe, Santini, Daniele, Sini, Valentina, Veltri, Enzo, Vaccaro, Angela, Ferrari, Laura, De Tursi, Michele, Tinari, Nicola, Grassadonia, Antonino, Greco, Filippo, Botticelli, Andrea, La Verde, Nicla, Zamagni, Claudio, Rubino, Daniela, Cortesi, Enrico, Magri, Valentina, Pomati, Giulia, Scagnoli, Simone, Capomolla, Elisabetta, Kayal, Ramy, Scinto, Angelo Fedele, Corsi, Domenico Cristiano, Cazzaniga, Marina, Laudadio, Lucio, Forciniti, Samantha, Mancini, Maria, Carbognin, Luisa, Seminara, Patrizia, Barni, Sandro, Samaritani, Riccardo, Roselli, Mario, Portarena, Ilaria, Dello Russo, Antonio, Ficorella, Corrado, Cannita, Katia, Carpano, Silvia, Pistelli, Mirco, Berardi, Rossana, De Maria Marchiano, Ruggero, Sperduti, Isabella, Ciliberto, Gennaro, Vici, Patrizia, Cassano, Alessandra (ORCID:0000-0002-3311-7163), Orlandi, Armando (ORCID:0000-0001-5253-4678), Corsi, Domenico, De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583), Pizzuti, Laura, Giordano, Antonio, Michelotti, Andrea, Mazzotta, Marco, Natoli, Clara, Gamucci, Teresa, De Angelis, Claudia, Landucci, Elisabetta, Diodati, Lucrezia, Iezzi, Laura, Mentuccia, Lucia, Fabbri, Agnese, Barba, Maddalena, Sanguineti, Giuseppe, Marchetti, Paolo, Tomao, Silverio, Mariani, Luciano, Paris, Ida, Lorusso, Vito, Vallarelli, Simona, Cassano, Alessandra, Airoldi, Francesca, Orlandi, Armando, Moscetti, Luca, Sergi, Domenico, Sarobba, Maria Giuseppina, Tonini, Giuseppe, Santini, Daniele, Sini, Valentina, Veltri, Enzo, Vaccaro, Angela, Ferrari, Laura, De Tursi, Michele, Tinari, Nicola, Grassadonia, Antonino, Greco, Filippo, Botticelli, Andrea, La Verde, Nicla, Zamagni, Claudio, Rubino, Daniela, Cortesi, Enrico, Magri, Valentina, Pomati, Giulia, Scagnoli, Simone, Capomolla, Elisabetta, Kayal, Ramy, Scinto, Angelo Fedele, Corsi, Domenico Cristiano, Cazzaniga, Marina, Laudadio, Lucio, Forciniti, Samantha, Mancini, Maria, Carbognin, Luisa, Seminara, Patrizia, Barni, Sandro, Samaritani, Riccardo, Roselli, Mario, Portarena, Ilaria, Dello Russo, Antonio, Ficorella, Corrado, Cannita, Katia, Carpano, Silvia, Pistelli, Mirco, Berardi, Rossana, De Maria Marchiano, Ruggero, Sperduti, Isabella, Ciliberto, Gennaro, Vici, Patrizia, Cassano, Alessandra (ORCID:0000-0002-3311-7163), Orlandi, Armando (ORCID:0000-0001-5253-4678), Corsi, Domenico, and De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583)
- Abstract
Data from 423 human epidermal growth factor receptor 2-negative (HER2−), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6–35.4) and clinical benefit was 52.7% (95% CI, 48–57.5). ORR was negatively affected by prior exposure to everolimus/exemestane (p = 0.002) and favorably influenced by early line-treatment (p < 0.0001). At 6 months, median progression-free survival was 12 months (95% CI, 8–16) and median overall survival was 24 months (95% CI, 17–30). More favorable outcomes were associated with palbociclib in early lines, no visceral metastases and no prior everolimus/exemestane. The main toxicity reported was neutropenia. Our results provide further support to the use of palbociclib with ET in HER2−, HR+ aBC. Differences in outcomes across patients subsets remain largely unexplained.
- Published
- 2019
24. A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study
- Author
-
Gamucci, Teresa, Pizzuti, Laura, Natoli, Clara, Mentuccia, Lucia, Sperduti, Isabella, Barba, Maddalena, Sergi, Domenico, Iezzi, Laura, Maugeri-Saccà, Marcello, Vaccaro, Angela, Magnolfi, Emanuela, Gelibter, Alain, Barchiesi, Giacomo, Magri, Valentina, D’Onofrio, Loretta, Cassano, Alessandra, Rossi, Ernesto, Botticelli, Andrea, Moscetti, Luca, Omarini, Claudia, Fabbri, Maria Agnese, Scinto, Angelo Fedele, Corsi, Domenico, Carbognin, Luisa, Mazzotta, Marco, Bria, Emilio, Foglietta, Jennifer, Samaritani, Riccardo, Garufi, Carlo, Mariani, Luciano, Barni, Sandro, Mirabelli, Rosanna, Sarmiento, Roberta, Graziano, Vincenzo, Santini, Daniele, Marchetti, Paolo, Tonini, Giuseppe, Di Lauro, Luigi, Sanguineti, Giuseppe, Paoletti, Giancarlo, Tomao, Silverio, De Maria Marchiano, Ruggero, Veltri, Enzo, Paris, Ida, Giotta, Francesco, Latorre, Agnese, Giordano, Antonio, Ciliberto, Gennaro, Vici, Patrizia, Cassano, Alessandra (ORCID:0000-0002-3311-7163), Corsi, Domenico Cristiano, Bria, Emilio (ORCID:0000-0002-2333-704X), De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583), Gamucci, Teresa, Pizzuti, Laura, Natoli, Clara, Mentuccia, Lucia, Sperduti, Isabella, Barba, Maddalena, Sergi, Domenico, Iezzi, Laura, Maugeri-Saccà, Marcello, Vaccaro, Angela, Magnolfi, Emanuela, Gelibter, Alain, Barchiesi, Giacomo, Magri, Valentina, D’Onofrio, Loretta, Cassano, Alessandra, Rossi, Ernesto, Botticelli, Andrea, Moscetti, Luca, Omarini, Claudia, Fabbri, Maria Agnese, Scinto, Angelo Fedele, Corsi, Domenico, Carbognin, Luisa, Mazzotta, Marco, Bria, Emilio, Foglietta, Jennifer, Samaritani, Riccardo, Garufi, Carlo, Mariani, Luciano, Barni, Sandro, Mirabelli, Rosanna, Sarmiento, Roberta, Graziano, Vincenzo, Santini, Daniele, Marchetti, Paolo, Tonini, Giuseppe, Di Lauro, Luigi, Sanguineti, Giuseppe, Paoletti, Giancarlo, Tomao, Silverio, De Maria Marchiano, Ruggero, Veltri, Enzo, Paris, Ida, Giotta, Francesco, Latorre, Agnese, Giordano, Antonio, Ciliberto, Gennaro, Vici, Patrizia, Cassano, Alessandra (ORCID:0000-0002-3311-7163), Corsi, Domenico Cristiano, Bria, Emilio (ORCID:0000-0002-2333-704X), and De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583)
- Abstract
We carried out a retrospective observational study of 264 HER2-positive advanced breast cancer (ABC) patients to explore the efficacy of first-line treatment with pertuzumab/trastuzumab/taxane in real-world setting. Survival data were analyzed by Kaplan Meier curves and log rank test. Median follow-up, length of pertuzumab/trastuzumab/taxane treatment and of pertuzumab, trastuzumab maintenance were 21, 4 and 15 months, respectively. The response rate was 77.3%, and the clinical benefit rate 93.6%. Median progression-free survival (mPFS) was 21 months, and median overall survival (mOS) was not reached. When comparing patients by trastuzumab-pretreatment, similar PFS were observed, although a longer OS was reached in trastuzumab-naïve patients (p = 0.02). Brain metastases at baseline and their development in course of therapy were associated with significantly shorter PFS (p = 0.0006) and shorter OS, although at a not fully statistically relevant extent (p = 0.06). The addition of maintenance endocrine therapy (ET) to pertuzumab/trastuzumab maintenance was associated with longer PFS (p = 0.0001), although no significant differences were detected in OS (p = 0.31). Results were confirmed by propensity score analysis (p = 0.003 and p = 0.46, respectively). In multivariate models, longer PFS was related to lower Performance Status (PS) (p = 0.07), metastatic stage at diagnosis (p = 0.006) and single metastatic site (p < 0.0001). An OS advantage was observed with lower PS (p < 0.0001), single metastatic site (p = 0.004), no prior exposure to trastuzumab (p = 0.004) and response to pertuzumab-based treatment (p = 0.003). Our results confirm that trastuzumab/pertuzumab/taxane is the standard of care as first-line treatment of patients with HER2-positive ABC even in the real-world setting. Moreover, the double-maintenance therapy (HER2 block and ET) is strongly recommended when feasible.
- Published
- 2019
25. HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies
- Author
-
Giorgi Rossi Paolo, Sideri Mario, Carozzi Francesca, Vocaturo Amina, Buonaguro Franco, Tornesello Maria, Burroni Elena, Mariani Luciano, Boveri Sara, Zaffina Leandra, and Chini Francesco
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Objective The aim of this study is to describe the prevalence of HPV types in invasive cervical cancers in Italy from 1996 to 2008. Methods A pooled analysis of the three largest case series typed to date was performed. HPV typing was performed on paraffin-embedded slices. Molecular analyses were performed in four laboratories. Multivariate analyses were performed to test the associations between calendar time, age, and geographical area and the proportion of types 16/18. Results Out of 574 cancers, 24 (4.2%) were HPV negative. HPV 16 and 18 were responsible for 74.4% (378/508) and 80.3% (49/61) of the squamous cancers and adenocarcinomas, respectively. Other frequent types were 31 (9.5%), 45 (6.4%), and 58 (3.3%) for squamous cancers and 45 (13.3%), 31, 35, and 58 (5.0%) for adenocarcinomas. The proportion of HPV 16 and/or 18 decreased with age (p-value for trend Conclusions The impact of HPV 16/18 vaccine on cervical cancer will be greater for early onset cancers. In vaccinated women, screening could be started at an older age without reducing protection.
- Published
- 2012
- Full Text
- View/download PDF
26. Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting
- Author
-
Di Benedetto, Anna, primary, Ercolani, Cristiana, additional, Pizzuti, Laura, additional, Angelucci, Domenico, additional, Sergi, Domenico, additional, Marinelli, Camilla, additional, Iezzi, Laura, additional, Sperati, Francesca, additional, Terrenato, Irene, additional, Mazzotta, Marco, additional, Mariani, Luciano, additional, Vizza, Enrico, additional, Paoletti, Giancarlo, additional, Tomao, Silverio, additional, Maugeri-Saccà, Marcello, additional, Barba, Maddalena, additional, Tinari, Nicola, additional, Natoli, Clara, additional, Ciliberto, Gennaro, additional, Grassadonia, Antonino, additional, and Vici, Patrizia, additional
- Published
- 2019
- Full Text
- View/download PDF
27. HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future
- Author
-
Venuti Aldo and Mariani Luciano
- Subjects
Medicine - Abstract
Abstract Although long-term protection is a key-point in evaluating HPV-vaccine over time, there is currently inadequate information on the duration of HPV vaccine-induced immunity and on the mechanisms related to the activation of immune-memory. Longer-term surveillance in a vaccinated population is needed to identify waning immunity, evaluating any requirements for booster immunizations to assess vaccine efficacy against HPV-diseases. Current prophylactic vaccines have the primary end-points to protect against HPV-16 and 18, the genotypes more associated to cervical cancer worldwide. Nevertheless, data from many countries demonstrate the presence, at significant levels, of HPVs that are not included in the currently available vaccine preparations, indicating that these vaccines could be less effective in a particular area of the world. The development of vaccines covering a larger number of HPVs presents the most complex challenge for the future. Therefore, long term immunization and cross-protection of HPV vaccines will be discussed in light of new approaches for the future.
- Published
- 2010
- Full Text
- View/download PDF
28. Human Papilloma Virus prevalence and type-specific relative contribution in invasive cervical cancer specimens from Italy
- Author
-
Lloveras Belén, Quirós Beatriz, Benevolo Maria, Vocaturo Amina, Marandino Ferdinando, Vizza Enrico, Alemany Laia, Monfulleda Núria, Mariani Luciano, Klaustermeier Jo, Quint Wim, de Sanjosé Silvia, and Bosch F Xavier
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Cervical cancer represents an important global public health problem. It is the 2nd most common cancer among women worldwide. Human Papillomavirus (HPV) infection is now well-established as a necessary cause of invasive cervical cancer (ICC) development. Only a few studies on HPV prevalence and type-specific distribution in ICC have been conducted in Italy. Aim To describe the prevalence of HPV and the HPV type-specific distribution in ICC cases identified in Rome, Italy. Methods 140 paraffin embedded tissue blocks of primary ICC diagnosed between 2001 and 2006 were identified at the Regina Elena Cancer Institute in Rome (Italy). HPV was detected through amplification of HPV DNA using SPF-10 HPV broad-spectrum primers followed by DEIA and then genotyping by LiPA25 (version 1). Results 134 cases were considered suitable for HPV DNA detection after histological evaluation; and overall, 90.3% (121/134) HPV prevalence was detected. 111 cases had a single HPV type, 4 cases had an uncharacterized type (HPVX) and 6 cases had multiple HPV infections. The five most common single HPV types among positive cases were: HPV16 (71/121; 58.7%), HPV18 (12/121; 9.9%), HPV31, HPV45 and HPV58 (5/121; 4.1% each). 2 (1.5%) of the single infections and 2 (1.5%) of the multiple infections contained low risk types. Statistically significant differences in the relative contribution of HPV18 were found when comparing squamous cell carcinomas with adenocarcinomas. Conclusions HPV16 and HPV18 accounted for almost 70% of all the HPV positive ICC cases. The study provides baseline information for further evaluation on the impact of recently introduced HPV vaccines in Italy.
- Published
- 2010
- Full Text
- View/download PDF
29. Vaccination and screening programs: harmonizing prevention strategies for HPV-related diseases
- Author
-
Pagliusi Sonia and Mariani Luciano
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract HPV vaccine is an exciting promise of the preventive medicine. Although HPV-immunization programs still reveal a number of unanswered questions, they represent a novel opportunity for primary prevention against cervical cancer and other HPV-related pre-neoplastic and neoplastic diseases. It is reasonable that the short and long-term benefits of vaccination on cervical and vulvo-vaginal HPV-related pathology will emerge when assuring over time a clear and complete information to the community and harmonizing the prevention strategies. Indeed, HPV-vaccination programs will require an understanding of new paradigms of infection and cancer control, and thus will require a rationale integration with the currently operating screening systems.
- Published
- 2008
- Full Text
- View/download PDF
30. Clinical and epidemiological correlates of antibody response to human papillomaviruses (HPVs) as measured by a novel ELISA based on denatured recombinant HPV16 late (L) and early (E) antigens
- Author
-
Costa Silvano, Mariani Luciano, Branca Margherita, Donà Maria, Accardi Luisa, Mochi Stefania, Grasso Felicia, Di Bonito Paola, Giorgi Colomba, Agarossi Alberto, Ciotti Marco, and Syrjänen Kari
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background At present, seroreactivity is not a valuable parameter for diagnosis of Human Papillomavirus (HPV) infection but, it is potentially valuable as marker of viral exposure in elucidating the natural history of this infection. More data are needed to asses the clinical relevance of serological response to HPV. Objectives The objective was to assess the clinical and epidemiological correlates of HPV-seroreactivity in a cohort of HIV-negative and HIV-positive women. Methods Seroreactivity of 96 women, evaluated in an ELISA test based on denatured HPV16 late (L) and early (E) antigens, was correlated with their clinical and epidemiological data previously collected for a multi-centre Italian study, HPV-PathogenISS study. Results No significant correlation was found between HPV DNA detection and seroreactivity. Women, current smokers showed significantly less seroreactivity to L antigens as compared with the non-smokers. HIV-positive women showed significantly less (66.7%) antibody response as compared with HIV-negative women (89.3%), with particularly impaired response to L antigens. Women, HIV-positive and current smokers, showed by far the lowest seroprevalence (33.3%) as compared to 75.9% among all other women (OR = 0.158; 95%CI 0.036–0.695, p = 0.014; Fisher's exact test). Importantly, this association did not loose its significance when controlled for confounding from age (continuous variable) in multivariate analysis or using Mantel-Haenszel test for age-groups. Conclusion It is tempting to speculate that HIV-positive current smokers comprise a special high-risk group, with highly impaired immunological response that could prevent eradication of persistent HPV infections and thus contribute to development of CIN3/CC.
- Published
- 2008
- Full Text
- View/download PDF
31. Serum antibody response to Human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins
- Author
-
Mariani Luciano, Costa Silvano, Branca Margherita, Donà Maria, Accardi Luisa, Mochi Stefania, Grasso Felicia, Di Bonito Paola, Agarossi Alberto, Ciotti Marco, Syrjänen Kari, and Giorgi Colomba
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Human papillomaviruses (HPVs) are the primary etiological agents of cervical cancer and are also involved in the development of other tumours (skin, head and neck). Serological survey of the HPV infections is important to better elucidate their natural history and to disclose antigen determinants useful for vaccine development. At present, the analysis of the HPV-specific antibodies has not diagnostic value for the viral infections, and new approaches are needed to correlate the antibody response to the disease outcome. The aim of this study is to develop a novel ELISA, based on five denatured recombinant HPV16 proteins, to be used for detection HPV-specific antibodies. Methods The HPV16 L1, L2, E4, E6 and E7 genes were cloned in a prokaryotic expression vector and expressed as histidine-tagged proteins. These proteins, in a denatured form, were used in ELISA as coating antigens. Human sera were collected from women with abnormal PAP smear enrolled during an ongoing multicenter HPV-PathogenISS study in Italy, assessing the HPV-related pathogenetic mechanisms of progression of cervical cancer precursor lesions. Negative human sera were collected from patients affected by other infectious agents. All the HPV-positive sera were also subjected to an avidity test to assess the binding strength in the antigen-antibody complexes. Results Most of the sera showed a positive reactivity to the denatured HPV16 proteins: 82% of the sera from HPV16 infected women and 89% of the sera from women infected by other HPV genotypes recognised at least one of the HPV16 proteins. The percentages of samples showing reactivity to L1, L2 and E7 were similar, but only a few serum samples reacted to E6 and E4. Most sera bound the antigens with medium and high avidity index, suggesting specific antigen-antibody reactions. Conclusion This novel ELISA, based on multiple denatured HPV16 antigens, is able to detect antibodies in women infected by HPV16 and it is not genotype-specific, as it detects antibodies also in women infected by other genital HPVs. The assay is easy to perform and has low cost, making it suitable for monitoring the natural history of HPV infections as well as for detecting pre-existing HPV antibodies in women who receive VLP-based HPV vaccination.
- Published
- 2006
- Full Text
- View/download PDF
32. Vulvar lichen sclerosus oncologic risk: italian interdisciplinary Society of Vulvology (SIIV) Position Paper.
- Author
-
Corazza, Monica, Salvini, Camilla, De Magnis, Angelina, Belfiore, Pina, Carriero, Carmine, Crippa, Stefano, Mariani, Luciano, Micheletti, Leonardo, Preti, Eleonora P., Radici, Gianluigi, Taddei, Gianluigi, Tosti, Giulio, Virgili, Annarosa, and Preti, Mario
- Published
- 2022
- Full Text
- View/download PDF
33. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor‐positive, advanced breast cancer: A real‐world experience
- Author
-
Pizzuti, Laura, primary, Giordano, Antonio, additional, Michelotti, Andrea, additional, Mazzotta, Marco, additional, Natoli, Clara, additional, Gamucci, Teresa, additional, De Angelis, Claudia, additional, Landucci, Elisabetta, additional, Diodati, Lucrezia, additional, Iezzi, Laura, additional, Mentuccia, Lucia, additional, Fabbri, Agnese, additional, Barba, Maddalena, additional, Sanguineti, Giuseppe, additional, Marchetti, Paolo, additional, Tomao, Silverio, additional, Mariani, Luciano, additional, Paris, Ida, additional, Lorusso, Vito, additional, Vallarelli, Simona, additional, Cassano, Alessandra, additional, Aroldi, Francesca, additional, Orlandi, Armando, additional, Moscetti, Luca, additional, Sergi, Domenico, additional, Sarobba, Maria Giuseppina, additional, Tonini, Giuseppe, additional, Santini, Daniele, additional, Sini, Valentina, additional, Veltri, Enzo, additional, Vaccaro, Angela, additional, Ferrari, Laura, additional, De Tursi, Michele, additional, Tinari, Nicola, additional, Grassadonia, Antonino, additional, Greco, Filippo, additional, Botticelli, Andrea, additional, La Verde, Nicla, additional, Zamagni, Claudio, additional, Rubino, Daniela, additional, Cortesi, Enrico, additional, Magri, Valentina, additional, Pomati, Giulia, additional, Scagnoli, Simone, additional, Capomolla, Elisabetta, additional, Kayal, Ramy, additional, Scinto, Angelo Fedele, additional, Corsi, Domenico, additional, Cazzaniga, Marina, additional, Laudadio, Lucio, additional, Forciniti, Samantha, additional, Mancini, Maria, additional, Carbognin, Luisa, additional, Seminara, Patrizia, additional, Barni, Sandro, additional, Samaritani, Riccardo, additional, Roselli, Mario, additional, Portarena, Ilaria, additional, Russo, Antonio, additional, Ficorella, Corrado, additional, Cannita, Katia, additional, Carpano, Silvia, additional, Pistelli, Mirco, additional, Berardi, Rossana, additional, De Maria, Ruggero, additional, Sperduti, Isabella, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional
- Published
- 2018
- Full Text
- View/download PDF
34. A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study
- Author
-
Gamucci, Teresa, primary, Pizzuti, Laura, additional, Natoli, Clara, additional, Mentuccia, Lucia, additional, Sperduti, Isabella, additional, Barba, Maddalena, additional, Sergi, Domenico, additional, Iezzi, Laura, additional, Maugeri-Saccà, Marcello, additional, Vaccaro, Angela, additional, Magnolfi, Emanuela, additional, Gelibter, Alain, additional, Barchiesi, Giacomo, additional, Magri, Valentina, additional, D’Onofrio, Loretta, additional, Cassano, Alessandra, additional, Rossi, Ernesto, additional, Botticelli, Andrea, additional, Moscetti, Luca, additional, Omarini, Claudia, additional, Fabbri, Maria Agnese, additional, Scinto, Angelo Fedele, additional, Corsi, Domenico, additional, Carbognin, Luisa, additional, Mazzotta, Marco, additional, Bria, Emilio, additional, Foglietta, Jennifer, additional, Samaritani, Riccardo, additional, Garufi, Carlo, additional, Mariani, Luciano, additional, Barni, Sandro, additional, Mirabelli, Rosanna, additional, Sarmiento, Roberta, additional, Graziano, Vincenzo, additional, Santini, Daniele, additional, Marchetti, Paolo, additional, Tonini, Giuseppe, additional, Di Lauro, Luigi, additional, Sanguineti, Giuseppe, additional, Paoletti, Giancarlo, additional, Tomao, Silverio, additional, De Maria, Ruggero, additional, Veltri, Enzo, additional, Paris, Ida, additional, Giotta, Francesco, additional, Latorre, Agnese, additional, Giordano, Antonio, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional
- Published
- 2018
- Full Text
- View/download PDF
35. The clinical implementation of primary HPV screening
- Author
-
Mariani, L, Igidbashian, S, Sandri, M, Vici, P, Landoni, F, Mariani, Luciano, Igidbashian, Sarah, Sandri, Maria Teresa, Vici, Patrizia, Landoni, Fabio, Mariani, L, Igidbashian, S, Sandri, M, Vici, P, Landoni, F, Mariani, Luciano, Igidbashian, Sarah, Sandri, Maria Teresa, Vici, Patrizia, and Landoni, Fabio
- Abstract
Objective: To evaluate, from a gynecology perspective, the transition from cytology-based HPV screening to primary HPV screening. Methods: Studies examining switching from cytology-based screening to primary HPV-DNA testing with triaging of patients with positive test results were retrieved and reviewed, with a particular focus on screening in an Italian setting. Results: The increased complexity of patient-management decisions when implementing HPV-based screening was a critical issue discussed in the literature. The change in strategy represents a paradigm shift in moving from a medical perspective of identifying the disease in individual patients, to a public-healthcare perspective of excluding HPV from the healthy population and identifying a small sub-group of individuals at increased risk of HPV. Conclusion: With knowledge about HPV screening evolving rapidly, new programs and related algorithms need to be sufficiently flexible to be adjusted according to ongoing research and the validation of new assays. The establishment of a national working group (including epidemiologists, gynecologists, pathologists, and healthcare providers) will be necessary to properly implement and govern this important technical and cultural transition.
- Published
- 2017
36. [Prevention of HPV cancer related through HPV-9: state of the art, potential benefits and open issues]
- Author
-
Mariani, Luciano, Bonanni, Paolo, Castiglia, Paolo, Chiamenti, Giampietro, Conforti, Giorgio, Conversano, Michele, Icardi, Giancarlo, Maio, Tommasa, Mennini, Francesco, Prato, Rosa, Scotti, Silvestro, Signorelli, Carlo, and Zuccotti, Gian Vincenzo
- Subjects
Female ,Humans ,Papillomavirus Infections ,Uterine Cervical Neoplasms ,Papillomavirus Vaccines - Abstract
HPV vaccines currently marketed in Italy (bivalent and quadrivalent against HPV 16-18 and HPV and 6,11,16,18 respectively) are an extraordinary tool for the primary prevention of HPV related diseases, particularly of the cervical cancer. Although the implementation of the organized vaccination programs has already translated (for some endpoint) in confirmation of clinical efficacy, remains excluded a significant proportion of the diseases linked to non-vaccine HPV types. The new nonavalent vaccine (HPV9), of impending commercialization, represents an evolution of the quadrivalent, the composition of which are added five high-risk HPV types (HPV 31,33,45,52,58). The high clinical-immunological efficacy in experimental trials against the new genotypes (96% for CIN2 +), and the equivalence immunogenic to the four already present in the previous vaccine, will render the use of HPV9 a tool able to control in an even more effective HPV disease. The potential of the new vaccine is linked to the reduction of the HPV cancer burden by 2-20% according to anatomical site, with major benefits for cervical cancer, vulvo-vaginal, penile and more limited benefits for anal tumours. Moreover, the potential benefits could be also linked to the reduction of incidence of pre-neoplastic lesions arising in the lower-genital tract, especially in the cervix (CIN2-3), so often cause lengthy and expensive diagnostic and therapeutic procedures. In the face of this broad provision of benefit from HPV9 vaccine, we have also to consider all the variables related to its introduction in the vaccination calendars: the market price, the schedule of administration (currently in three doses) and data regarding the cost-effectiveness. The authors recognize the new vaccine (currently registered only in the US) a lot of potential in the prevention of HPV-related diseases.
- Published
- 2016
37. Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk
- Author
-
Lauretta, Rosa, Lanzolla, Giulia, Vici, Patrizia, Mariani, Luciano, Moretti, Costanzo, and Appetecchia, Marialuisa
- Subjects
endocrine system diseases ,Article Subject ,nutritional and metabolic diseases - Abstract
Preclinical, early phase clinical trials and epidemiological evidence support the potential role of insulin-sensitizers in cancer prevention and treatment. Insulin-sensitizers improve the metabolic and hormonal profile in PCOS patients and may also act as anticancer agents, especially in cancers associated with hyperinsulinemia and oestrogen dependent cancers. Several lines of evidence support the protection against cancer exerted by dietary inositol, in particular inositol hexaphosphate. Metformin, thiazolidinediones, and myoinositol postreceptor signaling may exhibit direct inhibitory effects on cancer cell growth. AMPK, the main molecular target of metformin, is emerging as a target for cancer prevention and treatment. PCOS may be correlated to an increased risk for developing ovarian and endometrial cancer (up to threefold). Several studies have demonstrated an increase in mortality rate from ovarian cancer among overweight/obese PCOS women compared with normal weight women. Long-term use of metformin has been associated with lower rates of ovarian cancer. Considering the evidence supporting a higher risk of gynaecological cancer in PCOS women, we discuss the potential use of insulin-sensitizers as a potential tool for chemoprevention, hypothesizing a possible rationale through which insulin-sensitizers may inhibit tumourigenesis.
- Published
- 2016
- Full Text
- View/download PDF
38. LA MOTIVAZIONE NEGLI APPRENDIMENTI LINGUISTICI: APPROCCI TEORICI E IMPLICAZIONI PEDAGOGICHE
- Author
-
Mariani, Luciano
- Subjects
lcsh:Language and Literature ,lcsh:Philology. Linguistics ,lcsh:P1-1091 ,lcsh:P - Abstract
Il concetto di motivazione, in quanto costrutto multidimensionale, dinamico e socialmente costruito, è suscettibile di essere visto come una competenza che è possibile sviluppare lungo tutto il percorso formativo. Convinzioni e atteggiamenti possono costituire dei fattori particolarmente utili per esplorare i processi motivazionali, con riferimento ad aree complesse quali i rapporti tra motivazione, lingue e culture, tra motivazione e percezioni di sé e tra motivazione e compiti di apprendimento. Parallelamente, dal punto di vista operativo è utile considerare le strategie che insegnante e studente possono attivare, ciascuno nel proprio ruolo ma anche in una prospettiva di interdipendenza, per generare e mantenere la motivazione ad apprendere. L’illustrazione di alcuni fondamentali apporti teorici è accompagnata dalla citazione di affermazioni e di metafore di studenti, raccolte nel corso di alcuni sondaggi svolti sull’apprendimento delle lingue a scuola. MOTIVATION IN LANGUAGE LEARNING: THEORETICAL APPROACHES AND EDUCATIONAL IMPLICATIONS The concept of motivation as a multidimensional, dynamic and socially conditioned construct, can be seen as a competence which developed throughout the formative process. Beliefs and attitudes are particularly useful for exploring motivational processes, with special reference to complex areas such as the relationship between motivation, language and culture, motivation and the perception of the self, and motivation and learning tasks. In the same way, it is useful to consider the strategies that teachers and students can put into effect, maintaining their roles but also working interdependently, in order to generate and maintain the motivation to learn. Theoretical approaches to motivation are illustrated by statements and metaphors produced by students and collected during a series of surveys on the learning of languages in Italian school contexts., Italiano LinguaDue, Vol 4, No 1 (2012)
- Published
- 2012
39. How Human Papillomavirus Replication and Immune Evasion Strategies Take Advantage of the Host DNA Damage Repair Machinery
- Author
-
Bordignon, Valentina, primary, Di Domenico, Enea, additional, Trento, Elisabetta, additional, D’Agosto, Giovanna, additional, Cavallo, Ilaria, additional, Pontone, Martina, additional, Pimpinelli, Fulvia, additional, Mariani, Luciano, additional, and Ensoli, Fabrizio, additional
- Published
- 2017
- Full Text
- View/download PDF
40. Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference
- Author
-
Giorgi Rossi, Paolo, primary, Carozzi, Francesca, additional, Federici, Antonio, additional, Ronco, Guglielmo, additional, Zappa, Marco, additional, Franceschi, Silvia, additional, Barca, Alessandra, additional, Barzon, Luisa, additional, Baussano, Iacopo, additional, Berliri, Carla, additional, Bonanni, Paolo, additional, Boselli, Fausto, additional, Boveri, Sara, additional, Buonaguro, Franco Maria, additional, Burroni, Elena, additional, Carillo, Giuseppe, additional, Carretta, Elisa, additional, Chini, Francesco, additional, Confortini, Massimo, additional, Palma, Paolo Dalla, additional, Declich, Silvia, additional, Del Mistro, Annarosa, additional, Del Sole, Anna Maria, additional, Ferretti, Stefano, additional, Gabutti, Giovanni, additional, Gargiulo, Franco, additional, Giambi, Cristina, additional, Iannazzo, Stefania, additional, Iossa, Anna, additional, Levi, Miriam, additional, Lillo, Flavia, additional, Maccalini, Vincenzo, additional, Mangia, Maria Luisa, additional, Mariani, Luciano, additional, Naldoni, Carlo, additional, Ocello, Cristina, additional, Paci, Eugenio, additional, Pellegrini, Antonella, additional, Perino, Antonio, additional, Pezzarossi, Annamaria, additional, Pilia, Massimo, additional, Placidi, Antonio, additional, Pompa, Maria Grazia, additional, Russo, Francesca, additional, Sandri, Maria Teresa, additional, Sani, Cristina, additional, Scalisi, Aurora, additional, Schiboni, Maria Luisa, additional, Segnan, Nereo, additional, Sideri, Mario, additional, Spinillo, Arsenio, additional, Taddei, Gian Luigi, additional, Tornesello, Maria Lina, additional, Venturelli, Francesco, additional, Vocaturo, Amina, additional, and Zorzi, Manuel, additional
- Published
- 2017
- Full Text
- View/download PDF
41. TRA LINGUA E CULTURA: LA COMPETENZA PRAGMATICA INTERCULTURALE
- Author
-
Mariani, Luciano
- Subjects
lcsh:Language and Literature ,lcsh:Philology. Linguistics ,lcsh:P1-1091 ,lcsh:P - Abstract
Le interazioni sociali, verbali e non verbali, sono sempre regolate da norme culturali, per lo più implicite, il cui rispetto costituisce un presupposto di una comunicazione efficace. La competenza pragmatica interculturale studia queste norme e come esse condizionano i comportamenti comunicativi. Il contributo, dopo aver esaminato il ruolo di questa competenza nell’ambito più generale della competenza comunicativa, illustra il rapporto tra forme linguistiche e norme culturali, in particolare nella realizzazione degli atti linguistici e delle loro sequenze. Vengono quindi prese in considerazione le implicazioni pedagogiche e le possibili applicazioni didattiche nel processo di apprendimento e di insegnamento di una lingua seconda o straniera, fornendo da ultimo alcuni esempi di attività e materiali. Between language and culture: intercultural pragmatic competence Social interactions, both verbal and non-verbal, are always governed by (usually implicit) cultural norms, which are a prerequisite of effective communication. Intercultural pragmatic competence studies such norms and how they impact on communicative behaviours. This paper first examines the role of this competence within the scope of communicative competence. The relationship between language forms and cultural norms is then explored, with particular reference to the realization of speech acts and their sequences. Finally, pedagogical implications and possible teaching applications are discussed in the context of second and foreign language learning and teaching, together with some examples of relevant activities and materials., Italiano LinguaDue, Vol 7, No 1 (2015)
- Published
- 2015
- Full Text
- View/download PDF
42. Vaccinare per HPV: non solo le adolescenti e non solo profilassi. Review e position paper dell'Italian HPV Study Group (IHSG).
- Author
-
ORIGONI, Massimo, CRISTOFORONI, Paolo, MARIANI, Luciano, COSTA, Silvano, PRETI, Mario, SANDRI, Maria T., PRETI, Eleonora P., GHELARDI, Alessandro, and PERINO, Antonio
- Published
- 2019
- Full Text
- View/download PDF
43. Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment
- Author
-
Buglioni, Simonetta, Vici, Patrizia, Sergi, Domenico, Pizzuti, Laura, Di Lauro, Luigi, Antoniani, Barbara, Sperati, Francesca, Terrenato, Irene, Carosi, Mariantonia, Gamucci, Teresa, Vincenzoni, Cristina, Mariani, Luciano, Vizza, Enrico, Venuti, Aldo, Sanguineti, Giuseppe, Gadducci, Angiolo, Barba, Maddalena, Natoli, Clara, Vitale, Ilio, Mottolese, Marcella, De Maria Marchiano, Ruggero, Maugeri-Saccà, Marcello, De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583), Buglioni, Simonetta, Vici, Patrizia, Sergi, Domenico, Pizzuti, Laura, Di Lauro, Luigi, Antoniani, Barbara, Sperati, Francesca, Terrenato, Irene, Carosi, Mariantonia, Gamucci, Teresa, Vincenzoni, Cristina, Mariani, Luciano, Vizza, Enrico, Venuti, Aldo, Sanguineti, Giuseppe, Gadducci, Angiolo, Barba, Maddalena, Natoli, Clara, Vitale, Ilio, Mottolese, Marcella, De Maria Marchiano, Ruggero, Maugeri-Saccà, Marcello, and De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583)
- Abstract
Hippo is a tumor-suppressor pathway that negatively regulates the oncoproteins TAZ and YAP. Moreover, Hippo affects the biology of a variety of non-neoplastic cells in the tumor microenvironment, even including immune cells. We herein assessed the predictive role of TAZ and YAP, assessed by immunohistochemistry, in 50 cervical cancer patients prevalently treated with neoadjuvant chemotherapy. Tumors were classified as positive or negative according to the percentage of tumor-expressing cells and cellular localization. TAZ/YAP were also evaluated in non-neoplastic cells, namely endothelial cells, non-lymphocytic stromal cells and tumor-infiltrating lymphocytes (TILs). TAZ expression in cancer cells (TAZpos) was associated with a reduced pathological complete response (pCR) rate (p = 0.041). Conversely, the expression of TAZ and YAP in TILs (TAZTIL+and YAPTIL+) seemed to be associated with increased pCRs (p = 0.083 and p = 0.018, respectively). When testing the predictive significance of the concomitant expression of TAZ in cancer cells and its absence in TILs (TAZpos/TAZTIL-), patients with TAZpos/TAZTIL-showed lower pCR rate (p = 0.001), as confirmed in multivariate analysis (TAZpos/TAZTIL-: OR 8.67, 95% CI: 2.31â32.52, p = 0.001). Sensitivity analysis carried out in the 41 patients treated with neoadjuvant chemotherapy yielded comparable results (TAZpos/TAZTIL-: OR 11.0, 95% CI: 2.42â49.91, p = 0.002). Internal validation carried out with two different procedures confirmed the robustness of this model. Overall, we found evidence on the association between TAZ expression in cervical cancer cells and reduced pCR rate. Conversely, the expression of the Hippo transducers in TILs may predict increased treatment efficacy, possibly mirroring the activation of a non-canonical Hippo/MST pathway necessary for T-cells activation and survival.
- Published
- 2016
44. DNA damage and repair biomarkers in cervical cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis
- Author
-
Vici, Patrizia, Buglioni, Simonetta, Sergi, Domenico, Pizzuti, Laura, Di Lauro, Luigi, Antoniani, Barbara, Sperati, Francesca, Terrenato, Irene, Carosi, Mariantonia, Gamucci, Teresa, Dattilo, Rosanna, Bartucci, Monica, Vincenzoni, Cristina, Mariani, Luciano, Vizza, Enrico, Sanguineti, Giuseppe, Gadducci, Angiolo, Vitale, Ilio, Barba, Maddalena, De Maria Marchiano, Ruggero, Mottolese, Marcella, Maugeri-Saccà, Marcello, De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583), Vici, Patrizia, Buglioni, Simonetta, Sergi, Domenico, Pizzuti, Laura, Di Lauro, Luigi, Antoniani, Barbara, Sperati, Francesca, Terrenato, Irene, Carosi, Mariantonia, Gamucci, Teresa, Dattilo, Rosanna, Bartucci, Monica, Vincenzoni, Cristina, Mariani, Luciano, Vizza, Enrico, Sanguineti, Giuseppe, Gadducci, Angiolo, Vitale, Ilio, Barba, Maddalena, De Maria Marchiano, Ruggero, Mottolese, Marcella, Maugeri-Saccà, Marcello, and De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583)
- Abstract
Cervical cancer cells commonly harbour a defective G1/S checkpoint owing to the interaction of viral oncoproteins with p53 and retinoblastoma protein. The activation of the G2/M checkpoint may thus become essential for protecting cancer cells from genotoxic insults, such as chemotherapy. In 52 cervical cancer patients treated with neoadjuvant chemotherapy, we investigated whether the levels of phosphorylated Wee1 (pWee1), a key G2/M checkpoint kinase, and y-H2AX, a marker of DNA double-strand breaks, discriminated between patients with a pathological complete response (pCR) and those with residual disease. We also tested the association between pWee1 and phosphorylated Chk1 (pChk1), a kinase acting upstream Wee1 in the G2/M checkpoint pathway. pWee1, y-H2AX and pChk1 were retrospectively assessed in diagnostic biopsies by immunohistochemistry. The degrees of pWee1 and pChk1 expression were defined using three different classification methods, i.e., staining intensity, Allred score, and a multiplicative score. y-H2AX was analyzed both as continuous and categorical variable. Irrespective of the classification used, elevated levels of pWee1 and y-H2AX were significantly associated with a lower rate of pCR. In univariate and multivariate analyses, pWee1 and y-H2AX were both associated with reduced pCR. Internal validation conducted through a re-sampling without replacement procedure confirmed the robustness of the multivariate model. Finally, we found a significant association between pWee1 and pChk1. The message conveyed by the present analysis is that biomarkers of DNA damage and repair may predict the efficacy of neoadjuvant chemotherapy in cervical cancer. Further studies are warranted to prospectively validate these encouraging findings.
- Published
- 2016
45. HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy
- Author
-
Paolini, Francesca, primary, Curzio, Gianfranca, additional, Cordeiro, Marcelo Nazario, additional, Massa, Silvia, additional, Mariani, Luciano, additional, Pimpinelli, Fulvia, additional, de Freitas, Antonio Carlos, additional, Franconi, Rosella, additional, and Venuti, Aldo, additional
- Published
- 2016
- Full Text
- View/download PDF
46. Human papillomavirus 16 E2 interacts with neuregulin receptor degradation protein 1 affecting ErbB-3 expression in vitro and in clinical samples of cervical lesions
- Author
-
Paolini, Francesca, primary, Curzio, Gianfranca, additional, Melucci, Elisa, additional, Terrenato, Irene, additional, Antoniani, Barbara, additional, Carosi, Mariantonia, additional, Mottolese, Marcella, additional, Vici, Patrizia, additional, Mariani, Luciano, additional, and Venuti, Aldo, additional
- Published
- 2016
- Full Text
- View/download PDF
47. Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment
- Author
-
Buglioni, Simonetta, primary, Vici, Patrizia, additional, Sergi, Domenico, additional, Pizzuti, Laura, additional, Di Lauro, Luigi, additional, Antoniani, Barbara, additional, Sperati, Francesca, additional, Terrenato, Irene, additional, Carosi, Mariantonia, additional, Gamucci, Teresa, additional, Vincenzoni, Cristina, additional, Mariani, Luciano, additional, Vizza, Enrico, additional, Venuti, Aldo, additional, Sanguineti, Giuseppe, additional, Gadducci, Angiolo, additional, Barba, Maddalena, additional, Natoli, Clara, additional, Vitale, Ilio, additional, Mottolese, Marcella, additional, De Maria, Ruggero, additional, and Maugeri-Saccà, Marcello, additional
- Published
- 2016
- Full Text
- View/download PDF
48. DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis
- Author
-
Vici, Patrizia, primary, Buglioni, Simonetta, additional, Sergi, Domenico, additional, Pizzuti, Laura, additional, Di Lauro, Luigi, additional, Antoniani, Barbara, additional, Sperati, Francesca, additional, Terrenato, Irene, additional, Carosi, Mariantonia, additional, Gamucci, Teresa, additional, Dattilo, Rosanna, additional, Bartucci, Monica, additional, Vincenzoni, Cristina, additional, Mariani, Luciano, additional, Vizza, Enrico, additional, Sanguineti, Giuseppe, additional, Gadducci, Angiolo, additional, Vitale, Ilio, additional, Barba, Maddalena, additional, De Maria, Ruggero, additional, Mottolese, Marcella, additional, and Maugeri-Saccà, Marcello, additional
- Published
- 2016
- Full Text
- View/download PDF
49. HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions
- Author
-
Mariani, Luciano, primary, Sandri, Maria Teresa, additional, Preti, Mario, additional, Origoni, Massimo, additional, Costa, Silvano, additional, Cristoforoni, Paolo, additional, Bottari, Fabio, additional, and Sideri, Mario, additional
- Published
- 2016
- Full Text
- View/download PDF
50. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva
- Author
-
Laco, Jan, de Sanjose, Silvia, Alemany, Laia, Ordi, Jaume, Tous, Sara, Alejo, Maria, Bigby, Susan, Joura, Elmar, Maldonado, Paola, Bravo, Ignacio, Vidal, August, Guimera, Nuria, Cross, Paul, Wain, Gerard, Petry, Karl, Mariani, Luciano, Bergeron, Christine, Mandys, Vaclav, Sica, Adela, Felix, Ana, Usubutun, Alp, Seoud, Muhieddine, Hernandez-Suarez, Gustavo, Nowakowski, Andrzej, Wilson, Godfrey, Dalstein, Veronique, Hampl, Monika, Kasamatsu, Elena, Lombardi, Luis, Tinoco, Leopoldo, Alvarado-Cabrero, Isabel, Perrotta, Myriam, Bhatla, Neerja, Agorastos, Theodoros, Lynch, Charles, Goodman, Marc, Shin, Hai-Rim, Viarheichyk, Halina, Jach, Robert, Cruz, M.O.L., Velasco, Julio, Molina, Carla, Bornstein, Jacob, Ferrera, Annabelle, Domingo, Efren, Cheng-Yang, Choug, Banjo, Adekunbiola, Castellsague, Xavier, Pawlita, Michael, Lloveras, Belen, Quint, Wim, Mun oz, Nubia, Bosch, F., HPV VVAP study group, Orłowska-Heitzman, Jolanta, Kabzińska-Turek, Monika, Przybylska-Jurecka, Paulina, and Kula-Prykan, Marzena
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Genotype ,Vulvar Squamous Cell Carcinoma ,Biology ,Gastroenterology ,Polymerase Chain Reaction ,Vulva ,Human Papillomavirus DNA Tests ,Predictive Value of Tests ,Internal medicine ,medicine ,Biomarkers, Tumor ,Humans ,Neoplasm Invasiveness ,DNA Probes, HPV ,Genotyping ,Papillomaviridae ,Cyclin-Dependent Kinase Inhibitor p16 ,Retrospective Studies ,Gynecology ,Vulvar Neoplasms ,Papillomavirus Infections ,virus diseases ,Histology ,Vulvar cancer ,Middle Aged ,medicine.disease ,Immunohistochemistry ,female genital diseases and pregnancy complications ,Confidence interval ,Up-Regulation ,medicine.anatomical_structure ,Cross-Sectional Studies ,Logistic Models ,Oncology ,cardiovascular system ,Female ,Algorithms ,Carcinoma in Situ - Abstract
Background Human papillomavirus (HPV) contribution in vulvar intraepithelial lesions (VIN) and invasive vulvar cancer (IVC) is not clearly established. This study provides novel data on HPV markers in a large series of VIN and IVC lesions. Methods Histologically confirmed VIN and IVC from 39 countries were assembled at the Catalan Institute of Oncology (ICO). HPV-DNA detection was done by polymerase chain reaction using SPF-10 broad-spectrum primers and genotyping by reverse hybridisation line probe assay (LiPA 25 ) (version 1). IVC cases were tested for p16 INK4a by immunohistochemistry (CINtec histology kit, ROCHE). An IVC was considered HPV driven if both HPV-DNA and p16 INK4a overexpression were observed simultaneously. Data analyses included algorithms allocating multiple infections to calculate type-specific contribution and logistic regression models to estimate adjusted prevalence (AP) and its 95% confidence intervals (CI). Results Of 2296 cases, 587 were VIN and 1709 IVC. HPV-DNA was detected in 86.7% and 28.6% of the cases respectively. Amongst IVC cases, 25.1% were both HPV-DNA and p16 INK4a positive. IVC cases were largely keratinising squamous cell carcinoma (KSCC) ( N = 1234). Overall prevalence of HPV related IVC cases was highest in younger women for any histological subtype. SCC with warty or basaloid features (SCC_WB) ( N = 326) were more likely to be HPV and p16 INK4a positive (AP = 69.5%, CI = 63.6–74.8) versus KSCC (AP = 11.5%, CI = 9.7–13.5). HPV 16 was the commonest type (72.5%) followed by HPV 33 (6.5%) and HPV 18 (4.6%). Enrichment from VIN to IVC was significantly high for HPV 45 (8.5-fold). Conclusion Combined data from HPV-DNA and p16 INK4a testing are likely to represent a closer estimate of the real fraction of IVC induced by HPV. Our results indicate that HPV contribution in invasive vulvar cancer has probably been overestimated. HPV 16 remains the major player worldwide.
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.